John Paul Waymack
Director Técnico/Científico/I+D en MOLECULIN BIOTECH, INC. .
Cargos activos de John Paul Waymack
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| MOLECULIN BIOTECH, INC. | Director Técnico/Científico/I+D | - | - |
Pam-Bio Ltd.
 Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Director/Miembro de la Junta | - | - |
Historial de carrera de John Paul Waymack
Antiguos cargos conocidos de John Paul Waymack.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| PURPLE BIOTECH LTD | Presidente | 12/08/1968 | 01/07/2019 |
| Director Técnico/Científico/I+D | 12/08/1968 | 09/01/2020 | |
| Fundador | 12/08/1968 | 09/01/2020 | |
| University of Medicine & Dentistry of New Jersey | Corporate Officer/Principal | - | - |
| The United States Army Medical Service Corps | Corporate Officer/Principal | - | - |
Kitov Pharmaceuticals Ltd.
 Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Presidente | - | - |
| Director Técnico/Científico/I+D | - | - | |
| The University of Texas at Austin | Corporate Officer/Principal | - | - |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Israel | 4 |
Operativa
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 3 |
| Chairman | 2 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
| Distribution Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| PURPLE BIOTECH LTD | Health Technology |
| MOLECULIN BIOTECH, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
| The United States Army Medical Service Corps | |
Kitov Pharmaceuticals Ltd.
Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Distribution Services |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- John Paul Waymack
- Experiencia
